Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 22Terminated 5Unknown 2Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Colorectal Neoplasms 61Stomach Neoplasms 27Rectal Neoplasms 20Colonic Neoplasms 19Small Cell Lung Carcinoma 12Neoplasm Metastasis 11Pancreatic Neoplasms 10Locally Advanced Rectal Cancer 5Colorectal Cancer Metastatic 5Esophageal Squamous Cell Carcinoma 4Esophageal Neoplasms 4Biliary Tract Neoplasms 4Recurrence 3Liver Neoplasms 3Glioblastoma 3Gastrointestinal Neoplasms 3Cholangiocarcinoma 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Solid Tumors 2Sarcoma 2Lung Neoplasms 2Glioma 2Gallbladder Neoplasms 2Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction 2Advanced Colorectal Cancer 2mCRC 1Unspecified Adult Solid Tumor, Protocol Specific 1Thrombocytopenia 1Second Line Treatment of Gastric Cancer 1

Interventions

Temozolomide 16Radiotherapy 7apatinib 5anlotinib 3Surgical Procedures, Operative 3Chlorotoxin 3Bevacizumab 3Positron Emission Tomography Computed Tomography 2Pemetrexed 2Magnetic Resonance Spectroscopy 2Lomustine 2Irinotecan 2Immunotherapy, Adoptive 2Blood Specimen Collection 2Aminolevulinic Acid 2vandetanib 1sodium thiosulfate 1ribociclib 1poly ICLC 1lonafarnib 1lentiviral minigene vaccine of COVID-19 coronavirus 1etoposide phosphate 1Vinblastine 1Valproic Acid 1Tranexamic Acid 1Surveys and Questionnaires 1Sunitinib 1Rivaroxaban 1Radiosurgery 1Radiation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Glioma × Irinotecan × Clear all
NCT02848794 2017-06-16

Apatinib and Irinotecan in Treating Patients With Recurrent High-grade Glioma

The First People's Hospital of Lianyungang

Phase 1/2 Unknown
40 enrolled
CNS

Glioma

NCT01144988 2011-08-02

AVIRMA01-09

Medical University Innsbruck

Phase 2 Unknown
35 enrolled
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡